Background: U.S. HIV treatment guidelines recommend branded once-daily, 1-pill efavirenz-emtricitabine-tenofovir as first-line antiretroviral therapy (ART). With the anticipated approval of generic efavirenz in the United States, a once-daily, 3-pill alternative (generic efavirenz, generic lamivudine, and tenofovir) will decrease cost but may reduce adherence and virologic suppression.
Objective: To assess the clinical effect, costs, and cost-effectiveness of a 3-pill, generic-based regimen compared with a branded, coformulated regimen and to project the potential national savings in the first year of a switch to generic-based ART.
Design: Mathematical simulation of HIV disease.
Setting: United States.
Patients: HIV-infected persons.
Intervention: No ART (for comparison); 3-pill, generic-based ART; and branded ART.
Measurements: Quality-adjusted life expectancy, costs, and incremental cost-effectiveness ratios (ICERs) in dollars per quality-adjusted life-year (QALY).
Results: Compared with no ART, generic-based ART has an ICER of $21,100/QALY. Compared with generic-based ART, branded ART increases lifetime costs by $42,500 and per-person survival gains by 0.37 QALYs for an ICER of $114,800/QALY. Estimated first-year savings, if all eligible U.S. patients start or switch to generic-based ART, are $920 million. Most plausible assumptions about generic-based ART efficacy and costs lead to branded ART ICERs greater than $100,000/QALY.
Limitation: The efficacy and price reduction associated with generic drugs are unknown, and estimates are intended to be conservative.
Conclusion: Compared with a slightly less effective generic-based regimen, the cost-effectiveness of first-line branded ART exceeds $100,000/QALY. Generic-based ART in the United States could yield substantial budgetary savings to HIV programs.
Primary Funding Source: National Institute of Allergy and Infectious Diseases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664029 | PMC |
| http://dx.doi.org/10.7326/0003-4819-158-2-201301150-00002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Budget impact of antiretroviral therapy in a French clinic cohort.
AIDS
June 2017
aIAME, UMR 1137, INSERM, Paris Diderot University, Sorbonne Paris Cité bInfectious Diseases Clinic, Bichat-Claude Bernard University Hospital, AP-HP cCOREVIH Ile De France Nord, Paris dVirology Department, Bichat-Claude Bernard University Hospital, AP-HP ePharmaco-Toxicology Department, Bichat-Claude Bernard University Hospital, AP-HP fPharmacy/Patient Education Program on ART, Bichat-Claude Bernard University Hospital, AP-HP, Paris gAIDES, Paris hInstitute of Psychology - Lumière Lyon 2 University, GRePS - EA 4163, Bron iInternal Medicine, Bicêtre University Hospital, AP-HP, Le Kremlin-Bicêtre jINSERM U1018 - CESP, University Paris Sud, Le Kremlin-Bicêtre, France.
Objectives: In this study, we first assessed costs associated with the use of antiretroviral therapy (ART) in an infectious diseases University Hospital Clinic; second, we evaluated characteristics associated with these costs and finally simulated the impact on the overall ART budget of switching first-line and second-line regimens to less-costly regimens (as effective and well tolerated).
Design: Cohort analysis including persons living with HIV (PLHIV) aged at least 18 years on ART to estimate ART costs during 2014.
Methods: The current study was conducted in the Bichat-Claude Bernard University Hospital Clinic in Paris, France, where 4501 PLHIV consulted in 2014.
Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US.
HIV Clin Trials
November 2015
Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, USA.
Background: Value of Information (VOI) analysis examines whether to acquire information before making a decision. We introduced VOI to the HIV audience, using the example of generic antiretroviral therapy (ART) in the US.
Methods And Findings: We used a mathematical model and probabilistic sensitivity analysis (PSA) to generate probability distributions of survival (in quality-adjusted life years, QALYs) and cost for three potential first-line ART regimens: three-pill generic, two-pill generic, and single-pill branded.
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States.
Ann Intern Med
January 2013
Massachusetts General Hospital, Brigham and Women's Hospital, Harvard Medical School, Boston, USA.
Background: U.S. HIV treatment guidelines recommend branded once-daily, 1-pill efavirenz-emtricitabine-tenofovir as first-line antiretroviral therapy (ART).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!